Product
pacritinib
2 clinical trials
7 indications
Indication
Myelodysplastic SyndromesIndication
Primary MyelofibrosisIndication
Post-polycythemia Vera MyelofibrosisIndication
Chronic Myelomonocytic LeukemiaIndication
Polycythemia VeraIndication
Essential ThrombocytosisClinical trial
Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsStatus: Not yet recruiting, Estimated PCD: 2030-01-01
Clinical trial
Phase I Study Accessing the Safety of Pacritinib in Combination With Talazoparib in Patients With Myeloproliferative Neoplasms Unresponsive to Frontline JAK2 (Janus Kinase 2) InhibitionStatus: Recruiting, Estimated PCD: 2029-08-22